FDA
-
-
-
-
-
-
-
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus
-
-
-
-
-
-
-
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
-
-
-
-
-
-
-
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
-
-
-
-
-
-
-
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) Completes Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) Reports Successful Pre-IND Meeting with the FDA for CannQuit-N
-
-
-
-
-
-
-
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

